1
|
Wu FP, Wang YK, Li YP, Li M, Jia XL, Zhang X, Dang SS. [Clinical analysis of four cases of HBsAg seroconversion in patients with HBeAg-positive chronic hepatitis B after receiving interferon alpha therapy]. Zhonghua Gan Zang Bing Za Zhi 2021; 29:583-584. [PMID: 34225435 DOI: 10.3760/cma.j.cn501113-20200318-00123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- F P Wu
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Y K Wang
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Y P Li
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - M Li
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - X L Jia
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - X Zhang
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - S S Dang
- Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| |
Collapse
|
2
|
Cai DC, Pan C, Yu WH, Dang SS, Li J, Wu SM, Jiang N, Wang MR, Zhang ZH, Lin F, Xin SJ, Yang YF, Shen BS, Ren H. [Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 2019; 25:597-600. [PMID: 29056009 DOI: 10.3760/cma.j.issn.1007-3418.2017.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical effect and safety of entecavir capsules in the treatment of treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB). Methods: A total of 158 HBeAg-positive CHB patients were given oral entecavir capsules at a dose of 0.5 mg/time once a day for 144 weeks. Clinical outcome and safety were evaluated at baseline and at 24, 48, 72, 96, 120, and 144 weeks of treatment respectively. The Fisher's exact test was used for the analysis of categorical data. Results: After 144 weeks of treatment, 90.91% of all patients achieved virologic response (< 69 IU/ml), the normalization rate of alanine aminotransferase was 88.18%, the clearance rate of HBeAg was 33.33%, and the seroconversion rate of HBeAg was 24.07%. Of all patients, 2 dropped out due to adverse events and 5 experienced serious adverse reactions. Conclusion: Entecavir capsules can inhibit viral replication and have good safety in treatment-naïve HBeAg-positive CHB patients.
Collapse
Affiliation(s)
- D C Cai
- The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
| | - C Pan
- Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350000, China
| | - W H Yu
- The Eighth People's Hospital of Guangzhou, Guangzhou 510060, China
| | - S S Dang
- The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - J Li
- The Second People's Hospital of Tianjin, Tianjin 300192, China
| | - S M Wu
- Shanghai Public Health Clinical Center, Shanghai 201508, China
| | - N Jiang
- Sichuan Provincial People's Hospital, Chengdu 610772, China
| | - M R Wang
- No.81 Hospital of PLA, Nanjing 210002, China
| | - Z H Zhang
- Jinan Infectious Disease Hospital, Jinan 250021, China
| | - F Lin
- Hainan General Hospital, Haikou 570311, China
| | - S J Xin
- No.302 Hospital of PLA, Beijing 100039, China
| | - Y F Yang
- The Second Hospital of Nanjing, Nanjing 210003, China
| | - B S Shen
- The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - H Ren
- The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
| |
Collapse
|
3
|
McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LAM, Hillard CJ, Gorzalka BB. Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 2012; 237:333-7. [PMID: 23047058 DOI: 10.1016/j.bbr.2012.09.053] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Revised: 09/07/2012] [Accepted: 09/30/2012] [Indexed: 12/12/2022]
Abstract
Accumulating evidence has revealed that dysregulation of the endocannabinoid system could contribute to the development of major depression. Studies carried out post-mortem in depressed suicide victims have revealed increased CB(1) receptor binding site density in the prefrontal cortex (PFC). Accordingly, exposure of rodents to chronic unpredictable stress (CUS) results in phenotypic changes that mirror those of human depression, including increased CB(1) receptor binding site density in the PFC. Our goal in these studies was to examine the effects of CUS on the density of CB(1) receptor binding sites in the rodent medial PFC and to explore the role of this alteration in the behavioral changes invoked by CUS. Rodents exposed to CUS exhibited increased CB(1) receptor maximal binding site density (B(max)) within the ventromedial PFC, but not the dorsomedial PFC. To determine whether this change in the ventromedial PFC is an adaptive response, or alternatively, a consequence of chronic stress that contributes to the adoption of passive coping, we examined whether local CB(1) receptor blockade within the ventromedial PFC following CUS would significantly alter behaviors in the forced swim test (FST). CUS exposure significantly increased passive coping in the FST, and this was further augmented by discrete ventromedial PFC microinfusions of the CB(1) receptor antagonist AM251 prior to swim stress. Moreover, local CB(1) receptor blockade reduced active coping responses in CUS-exposed rats. These findings suggest that the increase in CB(1) receptor B(max) observed in the ventromedial PFC of rodents exposed to CUS maintains proactive coping strategies following chronic stress exposure.
Collapse
Affiliation(s)
- R J McLaughlin
- Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, BC, V6T 1Z4, Canada.
| | | | | | | | | | | | | |
Collapse
|